What were the major highlights of the quarterly results of Ajanta Pharma for the March 2022 quarter?
Answer
Answer
Home bred pharmaceutical company, Ajanta Pharma, saw sales grow by 15% for the Q4FY22 quarter at Rs870.29 crore. FY22 full year sales revenues were up 15.6% at Rs3,341 crore. Ajanta Pharma reported 13% higher India sales at Rs245 crore. In the fourth quarter, Ajanta Pharm witnessed growth across various business verticals. It grew by 11% in cardiology vertical, 25% in ophthalmology vertical, 17% in dermatology and 28% in pain management vertical. Pain management was the big growth story for the quarter.
Ajanta Pharma
Rs in Crore
Mar-22
Mar-21
YOY
Dec-21
QOQ
Total Income (Rs cr)
₹ 870.29
₹ 756.84
14.99%
₹ 837.91
3.86%
Net Profit (Rs cr)
₹ 151.21
₹ 159.26
-5.05%
₹ 191.78
-21.15%
Diluted EPS (Rs)
₹ 17.70
₹ 18.40
₹ 22.16
Net Margins
17.37%
21.04%
22.89%
The company did take a hit on the profitability front. Net profits for Q4FY22 fell -5.05% to Rs151.21 crore. This pressure was largely on the back of a spike raw material costs and manpower costs. Ajanta Pharma also reported a fall in EBITDA from Rs259 crore to Rs207 crore yoy, even as the EBITDA margins tapered to 24% in the quarter. Net margins stood at a level of 17.37% for the Q4FY22 compared to 21.04% in Q4FY21. Net profit margins or NPM were also lower sequentially as compared to 22.89% in Q3FY22.